Practice
Featured experience
Amazon.com $15 billion notes offering
We advised the underwriters on the offering
Circle $1.05 billion IPO
We are advising Circle on its IPO, the first IPO by a stablecoin issuer
Novartis $6 billion notes offering
We advised Novartis on the investment-grade debt offering
SailPoint $1.4 billion IPO
The shares are listed on the Nasdaq Global Select Market
Xspray Pharma SEK 265 million private placing of new shares
Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of…
Banco Votorantim $100 million reopening of notes under global MTN program
Davis Polk advised Banco Votorantim S.A. in connection with the offering of $100 million aggregate principal amount of its 4…
Decarbonization Plus Acquisition $200 million IPO
Davis Polk advised the underwriters in connection with the $200 million initial public offering of 20,000,000 units of…
Primo Water Holdings €450 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S…
Promigas and Gases del Pacífico $120 million notes offering
Davis Polk advised the initial purchasers in connection with the offering by Promigas S.A. E.S.P. and its subsidiary…
Morgan Stanley $1 billion inaugural offering of social bonds
Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $1 billion aggregate principal…
Aligos Therapeutics $150 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $150 million initial public…
Eargo $165.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9…
H.B. Fuller $300 million notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered debt issuance by H.B…
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17…